Securing America’s Medical Supply Chain and Advancing the Production of Life Saving Medicines Act

Bill: 116-s-3942
Sponsor: full_name: Sen. Loeffler, Kelly [R-GA]
Introduced: 2020-06-11
Policy area: Foreign Trade and International Finance
Subjects: Competitiveness, trade promotion, trade deficits

Congressional oversight

Executive agency funding and structure

Federal officials

Government employee pay, benefits, personnel management

Health technology, devices, supplies

Office of the U.S. Trade Representative

Prescription drugs

Trade agreements and negotiations
Latest action: action_date: 2020-06-11
text: Read twice and referred to the Committee on Finance.

Summaries:
action_date: 2020-06-11
action_desc: Introduced in Senate
text: <p><b>Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act </b></p> <p>This bill establishes the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the U.S. Trade Representative. The negotiator must conduct trade negotiations and enforce trade agreements related to pharmaceutical products and services and medical supply chains. </p>

tv_txt: II 116th CONGRESS 2d Session S. 3942 IN THE SENATE OF THE UNITED STATES June 11, 2020 Mrs. Loeffler introduced the following bill; which was read twice and referred to the Committee on Finance A BILL To establish the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the United States Trade Representative, to be responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, to advance domestic production of life-saving medicines, and to secure the United States medical supply chain to eliminate reliance on foreign governments, and for other purposes.

1. Short title This Act may be cited as the Securing America’s Medical Supply Chain and Advancing the Production of Life Saving Medicines Act . 2. Chief Pharmaceutical and Medical Supply Chain Negotiator (a) In general Section 141 of the Trade Act of 1974 ( 19 U.S.C. 2171 ) is amended— (1) in subsection (b)(2)— (A) by striking and one Chief Innovation and Intellectual Property Negotiator and inserting one Chief Innovation and Intellectual Property Negotiator, and one Chief Pharmaceutical and Medical Supply Chain Negotiator ; (B) by striking or the Chief Innovation and Intellectual Property Negotiator and inserting the Chief Innovation and Intellectual Property Negotiator, or the Chief Pharmaceutical and Medical Supply Chain Negotiator ; and (C) by striking and the Chief Innovation and Intellectual Property Negotiator and inserting the Chief Innovation and Intellectual Property Negotiator, and the Chief Pharmaceutical and Medical Supply Chain Negotiator ; and (2) in subsection (c), by adding at the end the following new paragraph: (7) The principal function of the Chief Pharmaceutical and Medical Supply Chain Negotiator shall be to conduct trade negotiations and to enforce trade agreements relating to United States pharmaceutical products and services and medical supply chains. The Chief Pharmaceutical and Medical Supply Chain Negotiator shall be a vigorous advocate on behalf of United States pharmaceutical and medical supply chain interests. The Chief Pharmaceutical and Medical Supply Chain Negotiator shall perform such other functions as the United States Trade Representative may direct. . (b) Compensation Section 5314 of title 5, United States Code is amended by striking Chief Innovation and Intellectual Property Negotiator, Office of the United States Trade Representative. and inserting the following: Chief Innovation and Intellectual Property Negotiator, Office of the United States Trade Representative. Chief Pharmaceutical and Medical Supply Chain Negotiator, Office of the United States Trade Representative. . (c) Report required Not later than one year after the appointment of the first Chief Pharmaceutical and Medical Supply Chain Negotiator pursuant to paragraph (2) of section 141(b) of the Trade Act of 1974, as amended by subsection (a), and annually thereafter, the United States Trade Representative shall submit to the Committee on Finance of the Senate and the Committee on Ways and Means of the House of Representatives a report describing in detail— (1) enforcement actions taken by the Trade Representative during the one-year period preceding the submission of the report to ensure the protection of United States pharmaceutical products and services and medical supply chains; and (2) other actions taken by the Trade Representative to advance United States pharmaceutical products and services and medical supply chain interests.